Market Spotlight: Glioblastoma
Market Spotlight: Glioblastoma
$1,318.00
This Market Spotlight report covers the Glioblastoma market, comprising key marketed and pipeline drugs, clinical trials, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Glioblastoma market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were approximately 77,000 incident cases of glioblastoma worldwide, and forecasts that number to increase to 91,800 incident cases by 2028.
- It is estimated that the majority of diagnosed cases were in males in 2019. Approved drugs in the glioblastoma space focus on DNA, vascular endothelial growth factor, DNA synthesis, protein synthesis, and RNA synthesis. These drugs are administered via the intravenous, intratumoral, and oral routes for GBM.
- The majority of industry-sponsored drugs in active clinical development for glioblastoma are in Phase II, with two drugs in the NDA/BLA phase.
- Therapies in mid- and late-stage development for glioblastoma focus on a wide variety of targets. The majority of pipeline drugs for glioblastoma are administered via the oral and intravenous routes.
- High-impact upcoming events for drugs in the glioblastoma space comprise topline Phase I/II trial results for Calquence, Phase III updated trial results for DCVax-Brain and trans sodium crocetinate (TSC), and an expected PDUFA date for biosimilar bevacizumab (Mylan/Biocon).
- The overall likelihood of approval of a Phase I solid tumors asset is 5.7%, and the average probability a drug advances from Phase III is 41.9%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
- There have been 42 licensing and asset acquisition deals involving glioblastoma drugs during 2015–20. The largest deal was the $1,119m exclusive licensing agreement signed in 2016 between Exelixis and Ipsen, pursuant to which Ipsen received exclusive commercialization rights to Exelixis’s current and potential future cabozantinib indications outside the US, Canada and Japan, including Cometriq.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for glioblastoma have been in the early and mid-phases of development, with 92% of trials in Phase I–II, and only 8% in Phase III–IV.
- The US has a substantial lead in the number of glioblastoma clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the glioblastoma space is dominated by completed trials. Merck & Co has the highest number of completed clinical trials for glioblastoma, with 78 trials.
- Merck & Co leads industry sponsors with the highest overall number of clinical trials for glioblastoma, followed by Roche.
CONTENTS
7 OVERVIEW
8 KEY TAKEAWAYS
9 DISEASE BACKGROUND
9 Disease definition
9 Patient segmentation
9 Symptoms
9 Risk factors
10 Diagnosis
11 TREATMENT
11 Surgery
11 Radiation therapy
11 Chemotherapy
11 Tumor-treating fields (TTFs)
12 Targeted therapy
13 EPIDEMIOLOGY
17 MARKETED DRUGS
20 PIPELINE DRUGS
36 RECENT EVENTS AND ANALYST OPINION
36 Toca 511 for Glioblastoma (September 12, 2019)
37 Opdivo for Glioblastoma (September 5, 2019)
38 Mvasi for Glioblastoma (June 25, 2019)
39 GammaTile for Glioblastoma (June 17, 2019)
41 Ripretinib for Glioblastoma (June 11, 2019)
42 AG-881 for Glioblastoma (June 3, 2019)
43 Multiple Drugs for Glioblastoma (June 3, 2019)
44 Opdivo for Glioblastoma (May 9, 2019)
46 Optune for Glioblastoma (April 23, 2019)
47 Optune for Glioblastoma (February 28, 2019)
48 Voyager ulRFE System for Glioblastoma (December 14, 2018)
49 SONOCLOUD for Glioblastoma (December 12, 2018)
51 Optune for Glioblastoma (December 1, 2018)
52 MDNA55 for Glioblastoma (October 31, 2018)
53 Optune for Glioblastoma (September 12, 2018)
55 KEY UPCOMING EVENTS
56 KEY REGULATORY EVENTS
56 Mylan Reveals FDA Goal Date For Bevacizumab
56 Pfizer Could Launch US Bevacizumab This Year Despite Patent Thicket
57 PROBABILITY OF SUCCESS
58 LICENSING AND ASSET ACQUISITION DEALS
58 HLB Takes First Expansion Step Via Immunomic Acquisition
59 Fosun Gains Chinese Rights To MimiVax’s SurVaxM
59 Deals Shaping The Medical Industry, October 2019
59 Tech Transfer Roundup: Mustang, Nationwide Children’s Hospital Collaborate In Pediatric Glioblastoma
61 PARENT PATENTS
63 REVENUE OPPORTUNITY
64 CLINICAL TRIAL LANDSCAPE
65 Sponsors by status
66 Sponsors by phase
67 Recent events
69 BIBLIOGRAPHY
70 Prescription information
71 APPENDIX
LIST OF FIGURES
15 Figure 1: Trends in incident cases of glioblastoma, 2019–28
20 Figure 2: Overview of pipeline drugs for glioblastoma in the US
20 Figure 3: Pipeline drugs for glioblastoma, by company
21 Figure 4: Pipeline drugs for glioblastoma, by drug type
21 Figure 5: Pipeline drugs for glioblastoma, by classification
37 Figure 6: Toca 511 for Glioblastoma (September 12, 2019): Phase III – Toca 5 (w/Lomustine)
38 Figure 7: Opdivo for Glioblastoma (September 5, 2019): Phase III – CheckMate-548
46 Figure 8: Opdivo for Glioblastoma (May 9, 2019): Phase III – CheckMate 498 (vs. Temozolomide)
53 Figure 9: MDNA55 for Glioblastoma (October 31, 2018): Phase IIb – MDNA55-05 (rGBM)
55 Figure 10: Key upcoming events in glioblastoma
57 Figure 11: Probability of success in the glioblastoma pipeline
58 Figure 12: Licensing and asset acquisition deals in glioblastoma, 2015-20
61 Figure 13: Parent Patents in glioblastoma
62 Figure 14: Parent patents in glioblastoma (continued)
64 Figure 15: Clinical trials in glioblastoma
64 Figure 16: Top 10 drugs for clinical trials in glioblastoma
65 Figure 17: Top 10 companies for clinical trials in glioblastoma
65 Figure 18: Trial locations in glioblastoma
66 Figure 19: Glioblastoma trials status
67 Figure 20: Glioblastoma trials sponsors, by phase
LIST OF TABLES
14 Table 1: Global incident cases of glioblastoma, 2019–28
16 Table 2: Incident cases of glioblastoma, by gender, 2019
18 Table 3: Marketed drugs for glioblastoma
22 Table 4: Pipeline drugs for glioblastoma in the US
36 Table 5: Toca 511 for Glioblastoma (September 12, 2019)
37 Table 6: Opdivo for Glioblastoma (September 5, 2019)
39 Table 7: Mvasi for Glioblastoma (June 25, 2019)
40 Table 8: GammaTile for Glioblastoma (June 17, 2019)
42 Table 9: Ripretinib for Glioblastoma (June 11, 2019)
43 Table 10: AG-881 for Glioblastoma (June 3, 2019)
44 Table 11: Multiple Drugs for Glioblastoma (June 3, 2019)
45 Table 12: Opdivo for Glioblastoma (May 9, 2019)
46 Table 13: Optune for Glioblastoma (April 23, 2019)
48 Table 14: Optune for Glioblastoma (February 28, 2019)
49 Table 15: Voyager ulRFE System for Glioblastoma (December 14, 2018)
50 Table 16: SONOCLOUD for Glioblastoma (December 12, 2018)
51 Table 17: Optune for Glioblastoma (December 1, 2018)
52 Table 18: MDNA55 for Glioblastoma (October 31, 2018)
54 Table 19: Optune for Glioblastoma (September 12, 2018)
63 Table 20: Historical global sales, by drug ($m), 2014–18
63 Table 21: Forecasted global sales, by drug ($m), 2020-24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the